BTIG Reiterates Buy Rating for ICU Medical, Inc. (ICUI)
BTIG maintains its bullish stance on ICU Medical with a $170 price target.
Key Points
- BTIG reiterated its buy rating for ICU Medical, Inc. (ICUI) on June 15, 2026, setting a price target of $170.
- ICU Medical shares were trading at $142.20, with a market cap of about $3.59 billion and a forward P/E ratio of 15.45.
- Recent insider activity included several executives buying and selling shares, while analysts from Needham and Keybanc also maintained buy ratings.
On June 15, 2026, BTIG reiterated its buy rating for ICU Medical, Inc. (NasdaqGS: ICUI) with a price target of $170. The stock traded at $142.20 following the reaffirmation of BTIG's bullish stance.
Other Institutional Activity in ICU Medical
BlackRock, Inc. grew its holdings by 20,167 shares, ending with 3,608,322 shares worth about $466 million. Janus Henderson Group PLC added 99,256 shares, bringing its total to 2,676,012 shares valued at approximately $346 million. Vanguard Portfolio Management LLC acquired 1,437,676 shares, reaching a total of 1,437,676 shares valued at about $186 million. Fuller & Thaler Asset Management, Inc. reduced its position by 45,260 shares, totaling 1,220,539 shares worth around $158 million. Dimensional Fund Advisors LP increased its stake by 63,026 shares, holding 983,802 shares valued at roughly $127 million.
ICU Medical Stock Snapshot
Shares of NasdaqGS: ICUI traded near $142.20. ICU Medical has a market cap of approximately $3.59 billion, a P/E ratio of 77.27, and a forward P/E of 15.45. The stock's 52-week range has been between $107.00 and $160.29, with a 50-day moving average of $128.15 and a 200-day moving average of $134.70. The company maintains a current ratio of 2.34 and a quick ratio of 0.95, with a debt-to-equity ratio of 63.62.
Recent Earnings
ICU Medical reported revenue of about $2.16 billion, with a revenue growth rate of -12.3%. The company posted an EPS of $1.86, achieving a net margin of 2.15% and a return on equity of 2.26%. The next earnings release is scheduled for August 6, 2026.
Insider Buying and Selling at ICU Medical, Inc.
On May 22, 2026, Daniel Woolson, President, sold 2,123 shares at an average price of $132.21. Virginia Ruth Sanzone, VP and General Counsel, sold 2,447 shares at $124.08 on May 14, 2026. On May 13, 2026, David Greenberg, Elisha Finney, and David Hoffmeister each bought 1,254 shares, with no average price listed.
Analysts Set New Price Targets
On June 15, 2026, BTIG reiterated its buy rating with a $170 price target. Earlier, Needham upgraded the stock to a buy with a $165 target on May 27, 2026. Keybanc maintained its buy rating with targets of $164 and $180 on April 27 and February 20, 2026, respectively. Piper Sandler also maintained a buy rating with targets of $163 and $178 on similar dates. The consensus among analysts is a buy rating, with a mean target price of $172.86 from seven analysts.
About ICU Medical, Inc.
ICU Medical, Inc., based in San Clemente, California, designs and manufactures medical products used in infusion therapy, vascular access, and vital care applications. Offerings include needle-free products, catheter devices, infusion pumps, and safety software. The company serves hospitals, clinics, and home health care providers globally. Led by CEO Mr. Vivek Jain, ICU Medical employs approximately 13,000 people.
Bottom Line
BTIG's reiteration of a buy rating with a $170 target price underscores its positive outlook on ICU Medical, Inc. Investors keep a close eye on such analyst updates to gauge market sentiment. Remember, 13F filings and analyst ratings are backward-looking and may not reflect current positions or opinions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.